Please wait a minute...
 Home  Journals Subscription Open Access About Us
中文
 
Just Accepted  |  Online First  |  Current Issue  |  Archive  |  Special Issues  |  Featured Articles  |  Most Downloaded
Journal of Translational Neuroscience    2019, Vol. 4 Issue (1) : 50-54     https://doi.org/10.3868/j. issn. 2096-0689. 2019. 01. 005
Case Report
Combination therapy of long-term tumor treating fields with temozolomide and bevacizumab prolongs survival in multifocal glioblastoma diagnosed patient: a case report
Damir Nizamutdinov1,3†, Kaiyang Feng1†, Amanda Johnson4, Ekokobe Fonkem1,2*
1.Department of Neurosurgery, Baylor Scott & White Health, Temple, Texas 76504, USA
2.Department of Surgery, College of Medicine, Texas A&M Health Science Center, Temple, Texas 76508, USA
3.Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A&M Health Science Center, Bryan, Texas 77807, USA
4.Houston Baptist University, Houston, Texas 77074, USA
Download: PDF(6876 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract The multifocal glioblastomas (GBM) are tumors with multiple discrete areas of contrast enhancing tumors which have considerably poorer prognosis than solitary GBM. Median overall survival of diagnosed patients almost twice as less than solitary presentation. We present a case report of multifocal GBM. A 72-year old right-handed male was evaluated at the Neuro-Oncology Clinic of Baylor Scott and White Hospital (Central Division). Patient presented at this hospital because of persistent progressive headaches, confusion, and an incident of fall. Physical evaluation revealed neurological impairments. Brain magnetic resonance imaging (MRI) revealed heterogeneous contrast enhancing lesions with associated vasogenic oedema. Patient underwent a stereotactic biopsy analysis of the larger lesion and pathology evaluation concluded an isocitrate dehydrogenase 1 and 2 wild type GBM with unmethylated O-6-methylguanine-DNA methyltransferase. Treatment remedies: Patient received 4 weeks concurrent radiation therapy along with combination of temozolomide at dose of 75 mg/m2 followed adjuvant temozolomide for 10 cycles with bevacizumab at 10 mg/kg every 2 weeks and Optune treatment. Post treatment evaluation: Repeat MRIs showed near complete resolution of the tumors at 26 months of treatment along with improvement of neurological status. Conclusion: Due to limitations of surgical manipulations in multifocal GBM diagnosed patients, combinational chemo and radiation therapy is the treatment of choice for most cases. Using additional novel treatment with non-invasive therapeutic device proven to be effective is another excellent approach to the established practice. Therefore, combination therapy of Optune plus temozolomide and bevacizumab might be a promising remedy for newly diagnosed multifocal glioblastomas.
Keywords multifocal glioblastoma      tumor treating fields      temozolomide      bevacizumab     
Issue Date: 25 March 2019
 Cite this article:   
Damir Nizamutdinov, Kaiyang Feng, Amanda Johnson, Ekokobe Fonkem. Combination therapy of long-term tumor treating fields with temozolomide and bevacizumab prolongs survival in multifocal glioblastoma diagnosed patient: a case report[J]. Journal of Translational Neuroscience,2019, 4(1): 50-54.
 URL:  
http://journal.hep.com.cn/jtn/EN/10.3868/j. issn. 2096-0689. 2019. 01. 005
http://journal.hep.com.cn/jtn/EN/Y2019/V4/I1/50
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
Copyright © 2014 Higher Education Press, All Rights Reserved. Powered by Beijing Magtech Co. Ltd
Service: 010-58556313 (Technology); 010-58556485 (Subscription) E-mail: subscribe@hep.com.cn